首页   >  
Angiogenesis/Protein Tyrosine Kinase
  >  
BTK

所有产品分类

所有产品

信号通路

研究领域

天然产物

抗体

多肽

催化剂

杂质对照品

医药中间体

基础原料

BTK

结构式 货号 产品名称 CAS号
Ibrutinib Racemate 结构式
 BCP24087 Ibrutinib Racemate 936563-87-0
Ibrutinib Racemate is the racemate of Ibrutinib.
Sunvozertinib 结构式
 BCP46584 Sunvozertinib 2370013-12-8
Sunvozertinib, also known as DZD9008, is an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor. Sunvozertinib shows activity against EGFRexon20ins and other mutations. In both cell lines and xenograft models, sunvozertinib shows potent antitumor activity. In the two ongoing phase I clinical studies, sunvozertinib was tolerated up to 400 mg once daily.
RN983 结构式
 BCP44110 RN983 1423129-83-2
RN983 is a selective BTK enzyme inhibitor.
BIIB068 结构式
 BCP44097 BIIB068 1798787-27-5
BIIB068 is a potent, selective, reversible and orally active BTK inhibitor.
TL-895 结构式
 BCP44090 TL-895 1415823-49-2
TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively.
Tolebrutinib 结构式
 BCP33289 Tolebrutinib 1971920-73-6
Tolebrutinib, also known as SAR442168, is a Bruton tyrosine kinase inhibitor.
Rilzabrutinib 结构式
 BCP43077 瑞扎布鲁替尼 1575596-29-0
Rilzabrutinib, also known as PRN1008, is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK).
Pirtobrutinib 结构式
 BCP42730 Pirtobrutinib 2101700-15-4
Pirtobrutinib is a Bruton's tyrosine kinase (BTK) inhibitor and antineoplastic agent.
CNX-500 结构式
 BCP40963 CNX-500 1202758-21-1
CNX-500 is a probe consisting of a covalent Btk inhibitor chemically linked to biotin.
Olmutinib dihydrochloride 结构式
 BCP38296 奥莫替尼双盐酸盐 1842366-97-5
Olmutinib is an orally available, mutant-selective third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed for treatment of advanced and metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC).
123下一页末页共 43 条记录 1 / 5 页 
2853530910